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Alzheimer’s disease (AD), the most common cause of dementia and neurodegeneration in the 32 
elderly, is characterized by deterioration of memory, executive and motor functions. 33 
Neuropathologic hallmarks of AD include neurofibrillary tangles, paired helical filaments and 34 
amyloid plaques. Mutations in the microtubule associated protein, Tau, a major component of the 35 
neurofibrillary tangles, cause its hyperphosphorylation in AD. We have shown that signaling by the 36 
gaseous signaling molecule, hydrogen sulfide (H2S), is dysregulated during aging. H2S signals via 37 
a posttranslational modification termed sulfhydration/persulfidation, which participates in diverse 38 
cellular processes. Here we show that cystathionine -lyase (CSE), the biosynthetic enzyme for 39 
H2S, binds wild type Tau, which enhances its catalytic activity. By contrast, CSE fails to bind Tau 40 
P301L, a mutant that is hyperphosphorylated in the 3xTg-AD mouse model of AD. We further show 41 
that CSE is depleted in 3xTg-AD mice as well as in human AD brains, H2S prevents phosphorylation 42 
of Tau by sulfhydrating its kinase, glycogen synthase kinase 3β (GSK3β). Finally, we demonstrate 43 
that sulfhydration is diminished in AD, while administering the H2S donor, sodium GYY4137 44 
(NaGYY), to the 3xTg-AD mice ameliorates motor and cognitive deficits in AD. 45 
Significance Statement 46 
Alzheimer’s disease (AD) is the leading cause of dementia in the elderly. Although dysregulated 47 
hydrogen sulfide (H2S) metabolism has been reported in AD, and H2S donors are beneficial, 48 
molecular mechanisms underlying neuroprotective effects of H2S are largely unknown. We now 49 
show that H2S confers neuroprotection by sulfhydrating GSK3β, to inhibit its activity, thereby 50 
preventing hyper-phosphorylation of Tau, a key pathogenic event in AD. Administering H2S donors 51 




Alzheimer’s disease (AD), the most prevalent neurodegenerative disorder, involves loss of memory 56 
and executive functions (1, 2). Currently no cure exists for AD, and clinical trials of diverse agents 57 
have largely failed to demonstrate therapeutic benefit (3, 4). AD may occur sporadically or have a 58 
genetic origin, with several mutations linked to a high risk for the disease (5). AD is characterized 59 
by aggregation of the microtubule associated protein, Tau and β-amyloid peptides, which are 60 
components of neurofibrillary tangles (NFTs) and amyloid plaques respectively (2, 3, 6). AD 61 
belongs to the class of diseases termed tauopathies, which include progressive supranuclear palsy 62 





disorders (FTLD) (7, 8). Tau was originally identified as a microtubule binding protein, which 64 
mediates assembly of microtubules (9). Tau undergoes several post-translational modifications in 65 
vivo, including phosphorylation, sumoylation and acetylation (10-13). Disease progression in AD is 66 
closely linked to Tau pathology (14, 15). Hyperphosphorylation of Tau, a hallmark of AD, decreases 67 
its binding to microtubules and causes its aggregation and mislocalization leading to neurotoxicity 68 
via multiple mechanisms, including changes in cytoskeletal architecture, axonal transport and 69 
mitochondrial respiration. (16-20).   70 
AD is associated with increased oxidative stress which promotes neurodegeneration (21). The 71 
reverse transsulfuration pathway leading to the synthesis of cysteine and glutathione (GSH) helps 72 
maintain redox homeostasis in the brain (Fig. 1A) and is dysregulated in neurotoxicity and 73 
neurodegeneration (22-26). Cystathionine -lyase (CSE) is the biosynthetic enzyme for the 74 
gaseous signaling molecule hydrogen sulfide (H2S) as well as its precursor cysteine (27)(Fig. 1A).  75 
CSE utilizes cystathionine which is synthesized from homocysteine by cystathionine β-synthase 76 
(CBS), to generate cysteine (28). Both CSE and CBS synthesize H2S in the brain, with CSE 77 
expressed in neurons and CBS in astrocytes (29). H2S is formed endogenously in almost all tissues 78 
and signals by sulfhydration/persulfidation (27, 30-33). Like  nitric oxide (NO) and carbon monoxide 79 
(CO), H2S is a gasotransmitter with pleiotropic roles (27, 34).   Apart from its role as an endothelial 80 
derived relaxation factor (EDRF), H2S has neuroprotective functions at physiological concentrations 81 
(34-37).  We have shown previously that disrupted metabolism of cysteine and H2S may be 82 
pathogenic in neurodegenerative conditions such as Parkinson’s disease (PD) and Huntington’s 83 
disease (HD) (24, 25, 38).  Sulfhydration is an evolutionarily conserved process, which is 84 
diminished during aging (39). Depletion of cysteine, a product of the reverse transsulfuration 85 
pathway, is also associated with aging and neurodegeneration (40, 41). We now report that the 86 
reverse transsulfuration pathway and persulfidation are dysregulated in AD while supplementation 87 
with H2S donors is beneficial. Moreover. motor and cognitive deficits are mitigated by administration 88 
of H2S donors. 89 
Results 90 
Dysregulation of the reverse transsulfuration pathway in AD 91 
Previously we reported altered H2S metabolism and sulfhydration patterns in PD, while 92 
administering H2S donors proved beneficial in mouse models of PD (9, 10). Similarly, in mouse 93 
models of AD, H2S donors reversed disease symptoms and improved spatial and cognitive deficits 94 
(42, 43).  We analyzed the expression of CSE in AD mouse models as well as human post-mortem 95 
samples. We utilized the 3xTg-AD mouse model of AD, which harbors the mutations PS1M146V, 96 
APPSwe and Tau P301L and develops both neurofibrillary tangles and amyloid plaques (44). CSE 97 





Moreover, we observed a 50% decrease in CSE expression in the cortex of AD postmortem brain 99 
(Fig. 1D). Using the dimedone-switch assay, we observed decreased levels of overall sulfhydration 100 
(Fig. 1E,F).  101 
CSE and CBS interact with wild type but not Tau P301L   102 
As H2S levels and sulfhydration are decreased in AD patients, we explored the interaction of CSE 103 
and CBS, the major H2S producing enzymes, with Tau and amyloid precursor protein (APP), 104 
proteins, which constitute the NFTs and amyloid plaques respectively. Neither CSE nor CBS bound 105 
APP (SI Appendix, Fig. S1A, B). In the adult brain Tau exists as six isoforms derived by alternative 106 
splicing (45) . We utilized full length Tau comprising 441 amino acid residues, which is also present 107 
in neurons (46)(Fig. 2A).  CSE and CBS bind to wild type Tau in HEK293 cells overexpressing CSE 108 
or CBS and Tau (Fig. 2B). Next, we studied the interaction of Tau and CSE, purified from bacterial 109 
cells (SI Appendix, Fig. S2).  Purified CSE and Tau also interacted, indicating that CSE binds Tau 110 
directly (Fig. 2C).  As the 3xTg-AD mouse model harbors the mutant, Tau P301L, we studied the 111 
binding of CSE and CBS to this mutant in HEK293 cells. Both CSE and CBS did not bind the P301L 112 
mutant of Tau (Fig. 2D). In the case of CBS, using GFP-Tau, we observed additional bands 113 
migrating above the band corresponding to GFP-Tau, likely reflecting non-specific bands (Fig. 2D). 114 
In the case of Flag-Tau, additional bands were not observed (Fig. 2B). As Tau is a neuronal protein 115 
and CSE, but not CBS, resides in neurons, with CBS being localized to astrocytes, we focused the 116 
remainder of our studies on CSE.   We analyzed the influence of Tau on CSE activity by measuring 117 
H2S production from L-cysteine in the presence of its cofactor, pyridoxal 5-phosphate (PLP). 118 
Purified tau enhanced H2S production from human recombinant CSE in vitro (Fig. 2E,F). We also 119 
measured H2S production (by supplementing with L-cysteine and PLP) from the lysates of HEK293 120 
cells transfected with CSE and Tau (Fig. 2G). CSE activity increased with time, and wild type Tau 121 
further augmented H2S generation by CSE (Fig. 2H). As CSE is the biosynthetic enzyme for H2S 122 
in neurons and signals by sulfhydration, we assessed whether Tau is sulfhydrated by CSE. Tau 123 
contains two cysteine residues, Cys291 and Cys322, which could be sulfhydrated (Fig. 2A). We 124 
monitored Tau sulfhydration in transfected HEK293 cells using the modified biotin switch assay 125 
(Fig. 2I), as well as the dimedone switch method in conjunction with mass spectrometry, which 126 
revealed that Tau is indeed sulfhydrated at C322 (SI Appendix, Fig. S5). 127 
H2S generated by CSE inhibits phosphorylation of Tau by glycogen synthase kinase β 128 
Tau harbors several sites which are phosphorylated by multiple kinases. Hyperphosphorylation of 129 
Tau decreases its affinity for microtubules and causes its aggregation. One of the major kinases 130 
which phosphorylates Tau is glycogen synthase kinase β (GSK3β), a serine/threonine kinase, 131 





modulate Tau phosphorylation by GSK3β.  To explore the effect of H2S on Tau phosphorylation, 133 
we utilized purified Tau, CSE and GSK3β in an in vitro assay (Fig. 3A).  Phosphorylation of Tau at 134 
Ser396 by GSK3β was significantly diminished when CSE in combination with L-cysteine and PLP, 135 
the substrate and cofactor for CSE respectively, were added to the reaction mixture (containing 136 
CSE, Tau and ATP as described in the Materials and Methods), indicating a role for H2S. Consistent 137 
with this observation,  phosphorylation of Tau was reduced when sodium hydrosulfide (NaSH) was 138 
added alone to GSK3β, Tau and ATP, in the absence of CSE, L-cysteine and PLP (Fig. 3A). To 139 
determine whether the cysteines in Tau affect its phosphorylation, we mutated these residues to 140 
serine and conducted the phosphorylation assays with GSK3β. Phosphorylation of the mutant, Tau 141 
C291S/C322S, was inhibited as well, indicating that absence of cysteine residues does not prevent 142 
the inhibition of Tau phosphorylation by GSK3β (Fig. 3B). As GSK3β is inhibited by phosphorylation 143 
of its Ser9 residue by the endogenous kinase, Akt, we explored whether the inhibitory effect of H2S 144 
on phosphorylation of Tau involves Ser9 of GSK3β. We utilized a constitutively active mutant of 145 
GSK3β, GSK3β S9A, wherein Ser9 is mutated to Ala (and therefore is not subject to inhibition by 146 
Akt) and examined the effect of H2S on phosphorylation of Tau. We analyzed Tau phosphorylation 147 
in HEK293 cells using the mutant, Tau P301L, which is a mutation present in the 3xTg-AD mouse 148 
model of AD (44). NaSH inhibited phosphorylation of Tau P301L even when GSK3β S9A was 149 
present, indicating that H2S acts by a mechanism independent of phosphorylation of GSK3β at 150 
Ser9 (Fig. 3C). Similarly, H2S also inhibited phosphorylation of the C291S/C322S mutant of Tau 151 
P301L in HEK293 cells, further confirming that inhibition of Tau phosphorylation does not require 152 
the cysteine residues on Tau (Fig. 3C). In HEK293 cells, phosphorylation of Tau resulted in its 153 
slower migration on gels, as reported previously (48). Treatment with NaSH inhibited 154 
phosphorylation at Ser396 and resulted in faster mobility of Tau P301L on the gel (Fig. 3C).  NaSH 155 
also inhibited phosphorylation of Tau at Ser202 and Thr205 (SI Appendix, Fig. S3A). Moreover, 156 
total Tau levels were increased in the GSK3β transfected samples, which may reflect stabilization 157 
of Tau P301L by GSK3β, which could result in increased accumulation of Tau and neurotoxicity. 158 
To further characterize inhibition of GSK3β activity by H2S, we conducted activity assays using 159 
radioactive [-32P]-ATP, GSK3β and a peptide substrate of GSK3β, monitoring phosphorylation of 160 
the peptide by scintillation counting. Like the assays conducted earlier, NaSH significantly inhibited 161 
phosphorylation of the peptide (SI Appendix, Fig. S3B). As HEK293 cells harbor other kinases such 162 
as extracellular signal-related kinase-1 and -2, and mitogen-activated protein kinases, p38 kinase 163 
and c-jun N-terminal kinase, which can also phosphorylate Tau, it remains to be determined 164 
whether H2S inhibits phosphorylation of Tau by these kinases (48). Thus, it appeared likely that 165 
H2S prevents phosphorylation of Tau by inhibiting GSK3β, possibly by sulfhydrating it. Therefore 166 
we examined the sulfhydration of GSK3β using mass spectrometry, revealing that GSK3β was 167 





GSK3β revealed that Cys218 lies close to Tyr216 which is phosphorylated in the kinase domain. 169 
Moreover, 3D-modeling showed that Cys218 lies close to Asp181 in the active site, which is 170 
involved in hydrogen bond formation for catalysis. Persulfidation or sulfhydration of Cys218 could 171 
disrupt the active site conformation (Fig. 3D,E). We analyzed sulfhydration of GSK3β in human AD 172 
samples using the dimedone switch assay in combination with an antibody array method we 173 
previously developed (39). In this method, a GSK3β antibody is immobilized on a 96 well plate with 174 
an N-hydroxysuccinimide (NHS)-activated surface as described previously (Fig. 3F) (39). 175 
Considering that proteins are labelled with 4-chloro-7-nitrobenzofurazan (NBF, green) reflecting 176 
total load and with cyanine-5 (Cy5, red) for sulfhydration, the ratio of these two signals would yield 177 
the observed levels of GSK3β sulfhydration. As a negative control 488-labelled albumin (instead of 178 
antibody) was used to block the available surface and then incubated with control lysates. The 179 
assay revealed that sulfhydration of GSK3β was significantly diminished in the cortex of AD 180 
patients, as compared to normal subjects (Fig. 3G,H). Sulfhydration of GSK3β was decreased 181 
almost two-fold in the cerebral cortex of AD patients, further confirming our observation that 182 
sulfhydration is decreased in AD.  183 
H2S donors alleviate behavioral symptoms in the 3xTg-AD mouse model 184 
To examine the neuroprotective effects of H2S in vivo, we administered NaGYY, a synthetic sodium 185 
salt derivative of Lawesson’s reagent, N-benzoylthiobenzamide, GYY4137 and a slow releasing 186 
H2S donor to 3xTg-AD mice (49-52). Commercially available GYY4137 is synthesized as a 187 
morpholine salt (morpholine is toxic and biologically active) and also contains undisclosed amounts 188 
of the  carcinogenic solvent (dichloromethane) which is metabolized to CO, potentially  complicating 189 
the interpretation of effects obtained. Accordingly, we utilized in-house ultrapure NaGYY (See 190 
Materials and Methods for additional details), which is devoid of these confounding effects and has 191 
been well characterized with the additional advantage of being water soluble (52, 53).  192 
Mice were treated either with NaGYY or saline (vehicle) at 6-mo via daily intraperitoneal injections 193 
(100 mg/kg in saline) for 12 wk. Levels of sulfhydration and behavioral studies were conducted 3-194 
mo after treatment with NaGYY at 9-mo. Overall levels of sulfhydration were decreased in the 3xTg-195 
AD mice, which was rescued in the 3xTg-AD mice treated with NaGYY (Fig. 4A). In addition, we 196 
observed that sulfhydration of immunoprecipitated Tau is decreased in AD mice and restored in 197 
NaGYY treated animals (Fig. 4B). Next, we studied the effects of the H2S donor on motor and 198 
cognitive functions of AD mice. We used an open field test to study the overall locomotor activity of 199 
3xTg-AD mice treated with the H2S donor. The AD mice had a reduced locomotor activity as 200 
compared to the wild type mice. NaGYY treatment enhanced overall locomotor activity of the AD 201 





although non-cognitive deficits, such as motor dysfunction, are also present and may even precede 203 
classical clinical symptoms (54). Motor symptoms have been observed in patients with autosomal 204 
dominant AD which correlate with disease progression (55).  Treatment with NaGYY partially 205 
rescued memory deficits of 3xTg-AD mice in the Barnes maze memory tests at 9-mo as compared 206 
to their vehicle (saline)-treated controls. The primary latency in the Barnes maze test was 207 
significantly improved, but there was no significant change in the primary, total error, or total latency 208 
in these mice (Fig. 4D-G).   Thus, the H2S donor NaGYY elicits beneficial effects on motor and 209 
cognitive deficits of AD mice.  210 
 211 
Discussion  212 
 213 
The principal finding of this study is that the gasotransmitter, H2S is neuroprotective in AD, by 214 
inhibiting phosphorylation of Tau via sulfhydration of GSK3β, the kinase for Tau. In addition, by 215 
sulfhydrating cysteine residues on target proteins, H2S prevents irreversible oxidation of cysteine 216 
residues as demonstrated previously (39).  Earlier we reported decreased H2S signaling by 217 
sulfhydration in PD, HD and during aging (24, 25, 39). Neuronal H2S produced by CSE mediates 218 
stress responses, which are compromised in neurodegenerative diseases (38, 56). 219 
H2S levels are tightly regulated in cells. Excess H2S deranges mitochondria and has been 220 
implicated in a state of suspended animation, attributed to inhibition of complex IV of the electron 221 
transport chain  (57, 58). The major H2S-producing enzymes are spatially compartmentalized in the 222 
adult brain, with CBS concentrated in astrocytes and CSE in neurons (29, 59). In amyotrophic 223 
lateral sclerosis (ALS) caused by the G93A mutation in superoxide dismutase 1 (SOD1) and in 224 
Down’s Syndrome (DS), excess H2S is neurotoxic (60-63). H2S donors are therapeutic in several 225 
AD models, however direct links to sulfhydration have not been established (43, 64-70).  226 
In this study, we detected diminished expression of CSE and sulfhydration in the AD brain. The 227 
3xTg-AD mouse model as well as postmortem cortex samples of AD patients display reduced 228 
sulfhydration. Supplementation with the slow releasing H2S donor, NaGYY rescues the diminished 229 
sulfhydration levels in the brains of 3xTg-AD mouse model and alleviates motor and cognitive 230 
deficits. Our findings concur with reports of diminished H2S levels in serum of AD patients and 231 
confirm the neuroprotective role of H2S donors in rodent models of AD (42, 43, 64, 65, 69, 71, 72). 232 
Treatment with H2S donors ameliorated several deficits including those in learning and memory.  233 
How might sulfhydration be neuroprotective? We propose that H2S sulfhydrates GSK3β, thereby 234 
inhibiting phosphorylation of Tau and preventing neurotoxicity (Fig. 4H).  As H2S participates in 235 
multiple signaling cascades, additional neuroprotective pathways may be involved (37). For 236 
example, the Nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway, which regulates 237 
response to oxidative stress response, may be enhanced by H2S. Under basal conditions, Nrf2 is 238 





it for proteasomal degradation (73). Keap1 has reactive cysteine residues, which, when 240 
sulfhydrated, causes its dissociation from Nrf2, which then translocates to the nucleus to transcribe 241 
genes involved in stress responses  (42, 74). Similarly, H2S modulates transcriptional regulatory 242 
networks which are disrupted in neurodegeneration (38, 75).  Stimulating the reverse 243 
transsulfuration pathway may be beneficial in AD. This pathway also leads to the production of 244 
glutathione, the cellular antioxidant, which regulates redox homeostasis and neurotransmission 245 
(76, 77). As the reverse transsulfuration pathway is a central hub in several neuroprotective 246 
signaling networks, its stimulation may afford therapeutic benefits by restoring redox balance and 247 
H2S metabolism (28, 41). This pathway is disrupted in several neurodegenerative diseases 248 
exhibiting impaired redox homeostasis. Thus in PD and HD, stimulating the production of cysteine 249 
and H2S via CSE is neuroprotective (24, 25, 38, 56). Aging is associated with diminished 250 
transsulfuration, and sulfhydration as well as elevated oxidative stress. We have shown previously 251 
that decreased sulfhydration and increased oxidation of cysteine residues on proteins occur across 252 
evolutionary boundaries during aging (39). Additionally, aging is the greatest risk factor for 253 
developing neurodegenerative diseases including AD (78). Accordingly, targeting the reverse 254 
transsulfuration pathway may afford therapeutic benefits for aging and neurodegenerative diseases 255 
involving suboptimal H2S signaling.  256 
 257 
 258 
Materials and Methods 259 
 260 
Cell cultures and reagents 261 
 262 
HEK293 cells were from American Tissue Culture Type Collection (ATCC). All chemicals were from 263 
Sigma unless mentioned otherwise. In this study we used a sodium salt of derivative of the slow 264 
release H2S donor, GYY4137 (NaGYY). Use of this compound was necessary, as commercial 265 
preparations of GYY4137 is a morpholine salt and complexed with unstated quantities of the 266 
carcinogenic solvent methylene chloride. Morpholine and dichloromethane (methylene chloride) 267 
are highly toxic and are not biologically inert with the latter well documented to be metabolized to 268 
carbon monoxide. Since sodium salts are pharmaceutically acceptable and non-toxic, we therefore 269 
synthesized NaGYY in-house as described previously by us to avoid these contaminants and 270 
impurities (51, 52). Lipofectamine 2000 (Invitrogen) was used for all transfection studies. The 271 
pRK5-eGFP-Tau (46904), pRK5-eGFP-Tau P301L (4690), pcDNA3-HA-GSK3β (14753), and 272 
pcDNA3-HA-GSK3β S9A (14754) constructs were obtained from Addgene.  273 
 274 
Immunoprecipitation assays and Western blot analysis 275 
HEK293 cells were transfected with indicated plasmids 24 h prior to lysis of the cells. Cells were 276 





% glycerol protease inhibitors (cOmplete™, EDTA-free Protease Inhibitor Cocktail from Sigma) and 278 
phosphatase inhibitors (PhosSTOP™ phosphatase inhibitor, Sigma) and lysates were cleared by 279 
centrifugation at 16,000 g for 10 min followed by recovery of the supernatant. Protein was quantified 280 
by Bradford assay and samples were normalized for protein content. Inputs were reserved and 500 281 
g of protein was incubated with GST beads overnight at 4 °C with rotation. Beads were washed 282 
four times in IP buffer, followed by elution into 1X  LDS buffer (Stock 4X containing 40% glycerol, 283 
4% lithium dodecyl sulfate (LDS), 0.8 M triethanolamine-Cl pH 7.6, 4% Ficoll®-400, 0.025% phenol 284 
red, 0.025% Coomassie G250, 2 mM EDTA disodium from Thermo Fisher Scientific, USA)   with 1 285 
mM DTT at 95 °C for 5 min. Samples and inputs were loaded on a mini NuPAGE 4-12% Bis-Tris 286 
gel (Thermo Fisher, Scientific USA) and electrophoresed   in  1X NuPAGE MES (2-(N-morpholino) 287 
ethanesulfonic acid) SDS running buffer (Thermo Fisher Scientific, USA) and immunoblotted with 288 
the indicated antibodies. Antibodies used include anti-CSE, generated in-house (36) (1: 4000), anti-289 
FLAG (1: 3000, Sigma), anti-GST-HRP (1:10,000, Sigma), anti-Tau (1: 1000, Santa Cruz 290 
Biotechnology), anti-GFP (1:1000, Cell Signaling Technology), anti-p396Tau (1:1000, Santa Cruz 291 
Biotechnology), anti-GSK3β (1: 1000, Santa Cruz Biotechnology), anti-β-actin HRP (1:10,000, 292 
Santa Cruz Biotechnology). For the in vitro immunoprecipitation assays, either anti-Tau antibody 293 
or normal mouse IgG control was incubated with Protein A/G agarose overnight at 4 °C with 294 
rotation. Antibody-agarose mixture was incubated with purified wild type Tau for 6 h at 4 °C with 295 
rotation, washed three times in IP buffer, and incubated with CSE overnight at 4 °C with rotation. 296 
Beads were washed four times in IP buffer followed by elution into LDS buffer with 1 mM DTT at 297 
95 °C for 5 min. Samples and inputs were analyzed by western blotting as described above. 298 
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MW, RT and the University of Exeter have patents (awarded/pending) on hydrogen sulfide delivery 314 
molecules and their therapeutic use.  315 
 316 
 317 
Figure Legends 318 
 319 
Fig. 1.  Cystathionine -lyase expression is decreased in Alzheimer’s disease. (A) The reverse 320 
transsulfuration pathway in mammals. Homocysteine, generated from dietary methionine, is 321 
condensed with serine to generate cystathionine by cystathionine β-synthase (CBS). Cystathionine 322 
is acted on by cystathionine -lyase (CSE) to produce cysteine. Cysteine can either be utilized to 323 
synthesize glutathione and other sulfur containing molecules or used as a substrate to generate 324 
hydrogen sulfide (H2S). Both homocysteine and cysteine may be utilized to produce H2S. While 325 
CSE may generate H2S from either cysteine or homocysteine, CBS produces H2S using a 326 
combination of cysteine and homocysteine. 3-mercaptopyruvate sulfur transferase (3-MST), in 327 
conjunction with cysteine amino transferase (CAT), a third enzyme, also produces H2S from 328 
cysteine. (B) CSE is depleted in the cortex of 24-mo 3xTg-AD mice. n=3, SEM, *P < 0.05. (C) CSE 329 
is depleted in the hippocampus of 3xTg-AD mice. n=3, SEM, *P < 0.05. (D) CSE is diminished in 330 
the cortex of AD patients (Braak stage 6). n=3, SEM, *P < 0.05. (E) The dimedone switch assay. 331 
Proteins were reacted with 4-chloro-7-nitrobenzofurazan (NBF-Cl), to label persulfides, thiols, 332 
sulfenic acids, and amino groups. Reaction with amino groups specifically results in a characteristic 333 
green fluorescence. Next, the NBF tag is switched by a dimedone-based probe, which emits red 334 
fluorescence (the Cy5 tag is shown as a red circle), selectively labeling persulfides. The mixture is 335 
then run on SDS gels and signals detected by fluorescence scanning. (F) Gel scan showing 336 




Fig. 2.  Cystathionine -lyase (CSE) binds the microtubule binding protein Tau. (A)  Schematic 341 
representation of full-length Tau, which is composed of 441 amino acids.  Tau harbors the N 342 
terminal domains, N1 and N2, a proline-rich region (PRR) and four repeat domains R1 through R4 343 
which bind microtubules. Two cysteine residues Cys291 and Cys322 are present in R2 and R3 344 
respectively. (B) Interaction of Tau with CSE and CBS. HEK293 cells were transfected with 345 
constructs encoding Flag tagged wild type Tau (Flag-Tau) and either GST tagged CSE or CBS or 346 
GST vector and GST pulldown assay conducted. GST-CSE and GST-CBS interact with Flag-Tau. 347 
(C) CSE binds Tau directly. In vitro coimmunoprecipitation assay using purified CSE and Tau. 348 
Normal IgG control was used as an isotype control for the anti-Tau antibody used in the 349 
immunoprecipitation. (D) CSE and CBS do not bind to mutant Tau P301L as revealed by co-350 





wild type Tau (WT) or mutant Tau P301L. Arrow with “s” indicates specific GFP-Tau band, arrow 352 
with “ns” indicates non-specific band. (E) Wild type Tau stimulates activity of CSE in vitro (using 353 
purified proteins) as measured by H2S production by the methylene blue assay. n=3, SEM, *P < 354 
0.05. (F) Kinetics of H2S production from human recombinant CSE without (black squares) or with 355 
Tau (red dots). CSE/Tau protein molar ratio is ½. Wild type Tau stimulates activity of CSE as 356 
assayed by a spectrophotometric assay utilizing 0.22 µM purified CSE and 0.44 µM in 100 mM 357 
HEPES buffer (pH 7.4) containing 0.4 mM lead acetate at 37 °C for 3 min and absorbance 358 
measured at 390 nm, reflecting the formation  lead sulfide formed by reaction of H2S with lead 359 
acetate. (G) Wild type Tau stimulates activity of CSE in HEK 293 cells in an in vitro reaction 360 
containing 10 mM L-cysteine and 250 M pyridoxal 5-phosphate (PLP) as measured by H2S 361 
production by the methylene blue assay. n=3, SEM, **P < 0.01. (H) WT Tau increases the activity 362 
of CSE in a time dependent manner. n=3, SEM, ***P < 0.001.  (I) Tau is sulfhydrated by H2S. Flag-363 
Tau was transfected into HEK293 and treated with 100 M NaSH and sulfhydration analyzed by 364 
the modified biotin switch assay. 365 
 366 
Fig. 3. CSE and H2S inhibit phosphorylation of Tau by GSK3β. (A)  Phosphorylation assays with 367 
purified Tau, GSK3β and CSE in vitro, in the presence or absence of L-cysteine (L-cys) and 368 
pyridoxal 5’-phosphate (PLP) or treated with 100 M NaSH.  Phosphorylation of Tau was assessed 369 
by western blotting using antibodies against phosphorylated Tau (pTau 396). Tau phosphorylation 370 
was significantly diminished when CSE, L-cysteine and PLP were added. Addition of NaSH alone, 371 
in the absence of CSE also prevented Tau phosphorylation. (B) Cysteine residues do not play a 372 
role in phosphorylation of Tau by GSK3β. Purified Tau or Tau C291S/C322S and GSK3β were 373 
incubated in the presence or absence of L-cysteine and PLP and analyzed for phosphorylation of 374 
Tau at Ser396. Western blot analysis revealed that mutation of cysteine residues Cys291 and 375 
Cys322 does not affect phosphorylation of Tau at Ser396. n=3, SEM, *P <0.05, ***P < 0.001. (C) 376 
H2S inhibits phosphorylation of P301L Tau by GSK3β. HEK293 cells were transfected with Tau 377 
P301L or Tau P301L C291S/C322S and GSK3β S9A and treated with 100 M NaSH for 24 h and 378 
analyzed for phosphorylation of Tau at Ser396 by western blotting. While GSK3β phosphorylated 379 
Tau, NaSH prevented this phosphorylation. (D) Ribbon Model of GSK3β (PDB:1j1b; 380 
DOI: 10.1107/S090744490302938X). Intercept: (E) Thiolate side chain of Cys218 (ball and stick 381 
model), that we found to be sulfhydrated, is already in a close proximity to Asp181 in the active site 382 
of GSK3β, so the presence of an additional sulfur atom will inevitably alter the conformation of the 383 
active site, which would inhibit its kinase activity. Oxygen atoms are shown in red, sulfur in yellow 384 
and nitrogen in blue. Dots around the atoms represent expected water surface accessibility. (F) 385 
Schematic representation of the antibody array-like approach to study sulfhydration status of 386 





surface. Brain cortical lysates from normal and AD post-mortem tissues were added to the wells to 388 
allow recognition of GSK3β from lysates by the antibody. The bound protein was labeled with NBF 389 
(green) for a total load and with Cy5 (red) for sulfhydration and the ratio of the two signals measured 390 
to yield sulfhydration levels. As a negative control 488-labelled albumin (instead of antibody) was 391 
used to block the available surface and then incubated with control lysates. (G) Read-out from a 392 
representative experiment showing decreased sulfhydration (red) in cortex of AD patients, while 393 
the negative control shows no signals.  The plate was recorded on Typhoon FL9500 at 488 nm 394 
(NBF fluorescence signal, green, which represents total load) and 635 nm (Cy5 signal (red), which 395 
represents sulfhydration). (H) Quantitation of H. n=4, SEM, ***P < 0.001. 396 
Fig. 4. The H2S donor, NaGYY ameliorates AD symptoms. (A) Overall sulfhydration is decreased 397 
in the hippocampus of 3xTg-AD mice, which is rescued by NaGYY treatment in 3xTg-AD mice as 398 
revealed by the dimedone switch method. n=3, SEM, ***P < 0.001. (B) Sulfhydration of Tau is 399 
decreased in the hippocampus of 3xTg-AD mice as revealed by immunoprecipitation assays in 400 
combination with the dimedone switch assay. Treatment with NaGYY rescues sulfhydration of Tau.  401 
(C) Treatment regimen for 3xTg-AD mice with the H2S donor, NaGYY. Mice were treated at 6-mo 402 
with 100 mg/kg NaGYY by intraperitoneal injection daily for 12 wk and behavioral analyses 403 
conducted at 9-mo. The open field test revealed significant deficits in locomotor activity in the male 404 
3xTg-AD mice, which were rescued by NaGYY. n=6-10, SEM, **P < 0.01 and *P < 0.05. (D-G) 405 
NaGYY partially rescues memory deficits in the 3xTg-AD mice.  These mice do not exhibit 406 
significant differences in primary error and total error in the Barnes Maze test (D,E). NaGYY 407 
treatment partially rescues primary and total latency (F,G). n=6-10, SEM, *P < 0.05 for comparison 408 
between primary latency of 3xTg-AD Saline and 3xTg-AD NaGYY by one-way ANOVA followed by 409 
a post-hoc Tukey test. (H) Model depicting a possible mode of neuroprotection afforded by H2S. 410 
GSK3β  (yellow-ochre) binds Tau (purple) and phosphorylates it  (depicted  as “P”), which leads to 411 
the formation of neurofibrillary tangles (NFTs) and AD pathology in the 3xTgAD mice. H2S produced 412 
by CSE (green) sulfhydrates GSK3β (“SH” in red text) and inhibits phosphorylation of Tau. Tau 413 
binds to CSE and enhances its activity (arrow with a “+” sign), forming part of a virtuous cycle that 414 
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Supplementary Information Text 
 
Materials and Methods 
 
Use of the H2S donor, NaGYY 
In this study we have used a sodium salt of an established H2S generating molecule, GYY4137, 
NaGYY (1, 2). The reasons for this were due to confounding chemicals present in commercial 
sources of GYY4137, sold through all major research chemical suppliers is a morpholine salt, 
present at a 1:1 ratio with the parent compound. However, morpholine itself is biologically active 
and highly toxic with a well characterized toxicity profile, and LD50 at doses commonly used for 
GYY4137 (e.g. 200-400 mg/kg i.p.; http://www.inchem.org/documents/ehc/ehc/ehc179.htm). As 
such its presence would confound interpretation of results generated. In addition, commercial 
GYY4137 contains an undisclosed amount of carcinogenic solvent (dichloromethane) present as 
part of the crystal lattice structure (as xCHCl2) and it is well known to be metabolized to carbon 
monoxide in vivo. This is particularly complicated since the CO and H2S have similar 
pharmacological properties and it is possible that many of the reported effects of commercially 
sourced GYY4137 in vivo may be due to CO rather than H2S. Moreover, with undisclosed amounts 
of dichloromethane (at least 0.5 molecules per molecule of GYY4137 (2), the molecular mass of 
commercial compound is not accurate e.g. molecular weight of commercial GYY4137 is 376.6 with 
additional unknown quantities of dichlromethane mwt-84.9 (so an additional 22% to the final mass.  
For these reasons, we have used the pharmaceutically more acceptable sodium salt which is 
devoid of these confounding chemicals (2, 3). The decomposition (hydrolysis) pathway and H2S 
generation are identical  and both salts are freely water soluble which offer considerable 
advantages over H2S releasing molecules which require organic solvents such as DMSO or ethanol 
(themselves biologically active) such as dithiolethione and thiohyrdoxybenzamide derivatives (1, 
2).  
 
Animals and treatment 
The 3xTg-AD mouse model was obtained from Jackson laboratories (Bar Harbor, Maine). Animals 
were housed on a 12-h light–dark schedule and received food and water ad libitum.6-mo old  3xTg-
AD mice and their wild type controls were injected with either 100 mg/kg NaGYY or vehicle (saline) 
intraperitoneally for 12 wk and behavioral studies conducted at 9-mo.  
 
Post-mortem brain samples 
Post-mortem samples from normal and AD patients (Braak stage 6) were obtained from the Johns 
Hopkins Brain Center from J. Troncoso and O. Pletnikova.  
 
 
Hydrogen sulfide production assays 
HEK293 cells were transfected with indicated plasmids for the indicated time periods. For 
experiments with purified protein, purified recombinant CSE and Tau was used. Lysates or purified 
proteins were incubated for 6 h at 37 °C purged with nitrogen in 100 mM K+ PBS, .5% Triton X-
100, 50 M pyridoxal phosphate, 10 mM cysteine. Samples were injected with 125 L 1% zinc 
acetate and 2.5 L 10 N NaOH and incubated shaking at RT for 1 h. 500 L of deionized water, 
100 L 20 mM N-N-dimethyl-p-phenylenediamine sulfate in 7.2M HCl, and 100 L 30 mM FeCl3 in 
1.2M HCl were added to each sample and absorbance at 670 nm was subsequently measured. In 
addition, production of H2S by CSE was measured in a spectrophotometric assay in which the 
reaction of H2S with lead acetate to form lead sulfide was monitored at 390nm (4).  Reaction buffer 
contained 1 mM of cysteine and 0.4 mM lead acetate in HEPES buffer (50 mM, pH 7.4) at 37 °C. 
hCSE (0.22 µM) or hCSE/hTau (0.22 µM/0.44 µM) were preincubated for 5 minutes at 37 °C (to 
allow the interaction and activation of the enzyme) before they were added into the buffer. H2S 
production was monitored for 30 minutes by measuring the absorbance spectrum every 4 seconds. 




Sulfhydration assays were conducted using the modified biotin switch assay, the dimedone switch 
assay and by mass spectrometry as described previously (5-7). Briefly, HEK293 cells were 
transfected with wild type Tau for 24 h and treated with 100 M NaSH for 24 h, as indicated. Cells 
were lysed in HEN buffer (250 mM HEPES–NaOH, pH 7.7, 1 mM EDTA, 0.1 mM Neocuproine) 
with 1% Triton X100, protease, and phosphatase inhibitors and cleared by centrifugation at 16,000 
g at 4 °C for 10 min. Protein was quantified by Bradford assay and samples were normalized for 
protein content. Sample free thiols were blocked in methyl methanethiosulfonate (MMTS) at 50 °C 
for 20 min with shaking. Protein in samples was precipitated with cold acetone and washed twice 
with at RT with 70% acetone. Protein pellets were resuspended in HENS (HEN buffer with 1% 
SDS) buffer and biotin-HPDP for biotinylation of sulfhydrated cysteines. Samples were incubated 
for 75 min at RT with rotation. Proteins were precipitated twice with cold acetone followed by 
resuspension in HENS buffer. Neutralization buffer (20 mM HEPES-NaOH, pH 7.7, 100 mM NaCl, 
1 mM EDTA, 0.5% Triton X-100) was added, and inputs were reserved for loading on SDS-PAGE. 
Neutravidin agarose beads were added to the samples and incubated at 4 °C overnight with 
rotation. Beads were washed with neutralization buffer with high salt (Neutralization buffer with 600 
mM NaCl) seven times followed by addition of elution buffer (20 mM HEPES-NaOH, pH 7.7, 100 
mM NaCl, 1 mM EDTA, 1% β-mercaptoethanol) and incubation at 95 °C for 5 min. LDS buffer with 
DTT was added and samples were loaded on SDS-PAGE and immunoblotted with indicated 
antibodies. The dimedone switch assay was conducted essentially as described earlier (6). 
Mass Spectrometry for Identification of Sulfhydrated Cysteines 
Purified GST-GSK3β was incubated with 100 uM NaSH in HEN buffer (HEPES–NaOH, pH 7.7, 
250 mM EDTA, 1 mM Neocuproine 0.1 mM) for 1 h at 37 °C followed by FASP digest on a 30 kDa 
filter by trypsin overnight at 37 °C. Filter was washed, acidified, and peptides were eluted with 60% 
ACN/.1% TFA and were run immediately on high-resolution mass spectrometry for analysis. MS-
MS spectra was searched using PEAKSX against the database created from MASCOT. Fragment 
Mass Error Tolerance was 0.012 Da and Parent Mass Error Tolerance was 6 ppm. MASCOT was 
set to search NP_002084.2 (glycogen synthase kinase-3 beta isoform 1 [Homo sapiens]). Human 
recombinant Tau 441 was incubated with H2O2 and H2S mixture to induce protein persulfidation 
and labeled with dimedone switch method as described earlier (39). Untreated samples served as 
a control. Proteins were subjected to trypsin digestion and LC/MS/MS analysis. Obtained spectra 
were analyzed with PEAKSX. The search settings were: precursor ∆m tolerance = 10 ppm, 
fragment ∆m tolerance = 0.2 Da, missed cleavages = 2, -10logP>50, modifications of lysine: NBF 
(163.0012), modifications of cysteine: NBF (163.0012), dimedone (138.0681),  
 
Purified Recombinant proteins 
WT Tau and Tau C291S/C322S were purified from BL21 bacterial cells transformed with pTrcHis-
Tau or pTrcHis-Tau C291S/C322S, respectively. Site-directed mutagenesis was carried out to 
generate the Tau mutant plasmid. Capturem His-Tagged Purification Maxiprep Columns (Takara) 
were used to purify the recombinant Tau proteins and visualized by SDS gel electrophoresis on 4-
12% Bis-Tris polyacrylamide gels, followed by Coomassie staining using SimplyBlue SafeStain 
(Thermo Fisher Scientific). GST-CSE was purified by affinity chromatography using glutathione-
agarose (Sigma) as per the manufacturer’s recommendations. 
 
Tau phosphorylation assays 
HEK293 cells were transfected with indicated plasmids for 24 h. Cells were treated with 100 M 
NaSH for 24 h and then lysed in IP buffer with clearance of lysates by centrifugation at 16,000 g 
for 10 min. Protein was quantified by Bradford assay and samples were normalized for protein 
content. LDS buffer with DTT was added and samples incubated at 95 °C for 5 min. Samples were 
loaded on SDS-PAGE and immunoblotted with indicated antibodies. For the in vitro assays, the 
kinase activity assay provided with the SignalChem GSK3β purified protein. Either 10 L of GSK3β 
(0.02 g/uL)  diluted in kinase dilution buffer III (KDBIII), containing 5 mM MOPS, pH 7.2, 2.5 mM 
β-glycerophosphate, 5 mM MgCl2, 1 mM EGTA, 0.4 mM EDTA and 50 ng/L BSA or 10 L of 
KDBIII, 5 L of 15 M purified Tau, and 5 L of dH2O or 0.5 mM NaSH  in dH2O (stock solution). 
Subsequently 5 L of 0.25 mM ATP was added to each reaction and incubated in the shaking 
incubator for 15 min at 30 °C. Next, LDS (+DTT) was added to stop the reactions and incubated at 
95 °C heat block for 5 min followed by Western blot analysis. 
 
Radioactive assay for determination of GSK3β activity:  For the radioactive in vitro assays, the 
kinase activity assay using GSK3β purified protein (SignalChem) was utilized. Either 10 L of 
GSK3β (0.02 g/uL)  diluted in kinase dilution buffer III (KDBIII), containing 5 mM MOPS, pH 7.2, 
2.5 mM β-glycerophosphate, 5 mM MgCl2, 1 mM EGTA, 0.4 mM EDTA and 50 ng/L BSA or 10 
L of KDBIII, 5 L of 15 M purified Tau, and 5 L of dH2O or 0.5 mM NaSH  in dH2O (stock 
solution). Subsequently 5 L of 0.25 mM [-32P] ATP (1 mCi/100 µl) was added to each reaction 
and incubated in the shaking incubator for 15 min at 30 °C. Next, the reaction mixture was spotted 
onto individually precut strips of phosphocellulose P81 paper, which were air dried and washed 
with 1% phosphoric acid in double distilled water and subjected to scintillation counting to estimate 
the radioactivity incorporated into the peptide.  
 
Mouse behavioral studies 
 
Barnes maze test:  6-mo old WT and 3xTg-AD mice were treated with daily intraperitoneal 
injections of NaGYY (100 mg/kg) or saline (vehicle) as indicated for 12 wk until behavioral assays 
were performed as indicated at 9-mo. Mice were trained on the Barnes Maze platform twice a day 
for four days followed by testing on the fifth and twelfth days. Training and testing were carried out 
as follows: mice were placed in the middle of a raised platform with visual cues in the periphery 
and 20 holes along the edge, one of which contained an escape path for the mouse. For a maximum 
of three min, the number of nose pokes into correct and incorrect holes as well as the time until the 
mouse nose poked the correct hole and the time until the mouse entered the escape path were 
recorded. If a mouse entered the escape path prior to the three-min limit, the session was cut short.  
 
Open field test. The mouse cohort used for the Barnes maze test was run on an open field 
chamber with IR beams recording their locomotor activity. Mice were allowed to freely roam the 
chamber for 45 min. 
 
Antibody array assessment of GSK3β sulfhydration. Antibody-array like detection of GSK3β 
sulfhydration from human brain samples. The GSK3β antibody (sc-377213, Santa Cruz) was 
immobilized on a 96 well plate with NHS-activated surface as described previously (6). Considering 
that proteins are labelled with NBF (green) for total load and with Cy5 (red) for sulfhydration, 
measuring the ratio of the two signals yields the levels of GSK3b sulfhydration. As a negative 
control 488-labelled albumin (instead of antibody) was used to block the available surface and then 
incubated with control lysates.  
 
Statistical Analysis. Results are presented as means ± SEM for at least three independent 
experiments. The sample sizes used were based on the magnitude of changes and consistency 
expected. Statistical significance was reported as appropriate. P values were calculated with 
Student’s t test. In behavioral analyses, the experimenter conducting the test was blinded to the 
genotype or treatment of the animals under study. Statistical significance was calculated using one-









Fig. S1. Amyloid precursor protein (APP) does not interact with cystathionine -lyase (CSE) and 
cystathionine -synthase (CBS). (A)  CSE does not bind APP. HEK293 cells were transfected with 
FLAG APP and either GST alone or GST-CSE for 24 h and GST pulldown conducted using 
glutathione agarose. Western blot analysis was performed after the pull-down, APP exists in cells 
as two forms, the immature form (imAPP), which is N-glycosylated and O-glycosylated. CSE does 
not bind to APP as seen in the pull-down (PD) using anti-FLAG antibodies. (B)  CBS does not bind 



















Fig. S2. Protein purification profiles of Tau, its mutants and cystathionine -lyase (CSE). (A)  
GST- tagged CSE was purified using glutathione agarose and analyzed by Coomassie staining.  
(B,C)  His-tagged wild type Tau and the double cysteine mutant, Tau C291S/C322S was purified 
using CaptureEm purification systems (Takara) and purity confirmed by SDS gel electrophoresis 
and Coomassie staing as described earlier.  
  
























Fig. S3. Glycogen synthase kinase 3 (GSK3) activity assays. (A) H2S inhibits phosphorylation of 
Tau P301L by GSK3β. HEK293 cells were transfected with Tau P301L or Tau 
P301LCys291/Cys322 and GSK3β and treated with 100 µM NaSH for 24 h and analyzed for 
phosphorylation of Tau at Ser202 and Thr205 by western blotting. While GSK3β phosphorylated 
Tau, NaSH prevented this phosphorylation.  (B) The H2S donor, NaSH prevents phosphorylation 
of a peptide substrate of Tau by GSK3β (YRRAAVPPSPSLSRHSSPHQpSEDEE, derived from 
glycogen synthase). Active GSK3β, peptide substrate and [-32P] -ATP were incubated at 30 °C for 


























Fig. S5. MS/MS spectra of sulfhydrated C322 containing peptide of Tau labelled with dimedone, 
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